With over two decades of pharmaceutical industry experience, I excel in strategically navigating benefit-risk profiles for diverse therapeutic modalities, from monoclonal antibodies to small molecules, and for various therapeutic areas including Oncology, Hematology, CNS, Infectious, Autoimmune, Diabetes, Liver & Metabolism, to name a few. My leadership style prioritizes people, fostering trust and collaboration at all levels. I am a forward-thinking leader in R&D strategy and tactical planning, and a highly regarded operational manager for key R&D functions. My Biopharma R&D expertise includes early development leadership of about 25 IND/IMPD programs, 7 NDA/MAA approvals, and a track record of efficiently developing therapeutic candidates. I have had impactful global regulatory interactions with FDA, MHRA, BfArM, ANSM, PMDA, Health Canada, TGA etc. during clinical development, partnership, and commercialization. Currently, I'm the Chief Development Officer at Concarlo Therapeutics, Inc., driving early-stage "pipeline in a target" towards clinical development. Previously, at Turning Point Therapeutics, Inc., (acquired by BMS, $4.6B)I led a lean, outsourced DevSci function, contributing to a $2B+ valuation and a $200M follow-on offering. In addition, my background spans leadership roles at Jazz Pharmaceuticals, Inc., NGM Biopharmaceuticals, Inc., Genentech, Celera Genomics and other industry leaders. My education includes a Ph.D. in Pharmacology/Toxicology and certification from the American Board of Toxicology. I volunteer for California Life Sciences as their Scientific Advisor on FAST program. I also advise startups through Home lab UCSD, founders corner, and connect San Diego. I am a member of the WIB Board Room Ready 2023 cohort, CEOThreeSixty, and Bullpen. As a dedicated member of professional organizations like the American College of Toxicology and Society of Toxicology, I actively contribute to advancing the field. I thrive in fast-paced environments, leveraging a strategic mindset and a biotech approach to achieve results. With over two decades of pharmaceutical industry experience, I excel in strategically navigating benefit-risk profiles for diverse therapeutic modalities, from monoclonal antibodies to small molecules, and for various therapeutic areas including Oncology, Hematology, CNS, Infectious, Autoimmune, Diabetes, Liver & Metabolism, to name a few. My leadership style prioritizes people, fostering trust and collaboration at all levels. I am a forward-thinking leader in R&D strategy and tactical planning, and a highly regarded operational manager for key R&D functions. My Biopharma R&D expertise includes early development leadership of about 25 IND/IMPD programs, 7 NDA/MAA approvals, and a track record of efficiently developing therapeutic candidates. I have had impactful global regulatory interactions with FDA, MHRA, BfArM, ANSM, PMDA, Health Canada, TGA etc. during clinical development, partnership, and commercialization. Currently, I'm the Chief Development Officer at Concarlo Therapeutics, Inc., driving early-stage "pipeline in a target" towards clinical development. Previously, at Turning Point Therapeutics, Inc., (acquired by BMS, $4.6B)I led a lean, outsourced DevSci function, contributing to a $2B+ valuation and a $200M follow-on offering. In addition, my background spans leadership roles at Jazz Pharmaceuticals, Inc., NGM Biopharmaceuticals, Inc., Genentech, Celera Genomics and other industry leaders. My education includes a Ph.D. in Pharmacology/Toxicology and certification from the American Board of Toxicology. I volunteer for California Life Sciences as their Scientific Advisor on FAST program. I also advise startups through Home lab UCSD, founders corner, and connect San Diego. I am a member of the WIB Board Room Ready 2023 cohort, CEOThreeSixty, and Bullpen. As a dedicated member of professional organizations like the American College of Toxicology and Society of Toxicology, I actively contribute to advancing the field. I thrive in fast-paced environments, leveraging a strategic mindset and a biotech approach to achieve results.

• 

  Chief Development Officer in Concarlo Therapeutics

  Developing solutions for drug-resistant cancer